Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 357

1.

Simple and cost-effective liquid chromatography-mass spectrometry method to measure dabrafenib quantitatively and six metabolites semi-quantitatively in human plasma.

Vikingsson S, Dahlberg JO, Hansson J, Höiom V, Gréen H.

Anal Bioanal Chem. 2017 Apr 20. doi: 10.1007/s00216-017-0316-8. [Epub ahead of print]

PMID:
28429064
2.

Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma.

de Coaña YP, Wolodarski M, Poschke I, Yoshimoto Y, Yang Y, Nyström M, Edbäck U, Brage SE, Lundqvist A, Masucci GV, Hansson J, Kiessling R.

Oncotarget. 2017 Mar 28;8(13):21539-21553. doi: 10.18632/oncotarget.15368.

3.

Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma.

Helgadottir H, Kis L, Ljungman P, Larkin J, Kefford R, Ascierto PA, Hansson J, Masucci G.

Ann Oncol. 2017 Apr 12. doi: 10.1093/annonc/mdx177. [Epub ahead of print] No abstract available.

PMID:
28407116
4.

More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments.

Kandolf Sekulovic L, Peris K, Hauschild A, Stratigos A, Grob JJ, Nathan P, Dummer R, Forsea AM, Hoeller C, Gogas H, Demidov L, Lebbe C, Blank C, Olah J, Bastholt L, Herceg D, Neyns B, Vieira R, Hansson J, Rutkowski P, Krajsova I, Bylaite-Bucinskiene M, Zalaudek I, Maric-Brozic J, Babovic N, Banjin M, Putnik K, Weinlich G, Todorovic V, Kirov K, Ocvirk J, Zhukavets A, Kukushkina M, De La Cruz Merino L, Ymeri A, Risteski M, Garbe C.

Eur J Cancer. 2017 Apr;75:313-322. doi: 10.1016/j.ejca.2017.01.012. Epub 2017 Mar 4.

PMID:
28264791
5.

Symptom Management of the Patient with CKD: The Role of Dialysis.

Cabrera VJ, Hansson J, Kliger AS, Finkelstein FO.

Clin J Am Soc Nephrol. 2017 Apr 3;12(4):687-693. doi: 10.2215/CJN.01650216. Epub 2017 Feb 1.

PMID:
28148557
6.

Doxorubicin enhances the capacity of B cells to activate T cells in urothelial urinary bladder cancer.

Zirakzadeh AA, Kinn J, Krantz D, Rosenblatt R, Winerdal ME, Hu J, Hartana CA, Lundgren C, Bergman EA, Johansson M, Holmström B, Hansson J, Sidikii A, Vasko J, Marits P, Sherif A, Winqvist O.

Clin Immunol. 2017 Mar;176:63-70. doi: 10.1016/j.clim.2016.12.003. Epub 2016 Dec 24.

PMID:
28025135
7.

Capillary Pumping Independent of Liquid Sample Viscosity.

Guo W, Hansson J, van der Wijngaart W.

Langmuir. 2016 Dec 6;32(48):12650-12655. Epub 2016 Nov 14.

PMID:
27798835
8.

Sentinel node detection in muscle-invasive urothelial bladder cancer is feasible after neoadjuvant chemotherapy in all pT stages, a prospective multicenter report.

Rosenblatt R, Johansson M, Alamdari F, Sidiki A, Holmström B, Hansson J, Vasko J, Marits P, Gabrielsson S, Riklund K, Winqvist O, Sherif A.

World J Urol. 2016 Oct 13. [Epub ahead of print]

PMID:
27738804
9.

Overexpression of Functional SLC6A3 in Clear Cell Renal Cell Carcinoma.

Hansson J, Lindgren D, Nilsson H, Johansson E, Johansson M, Gustavsson L, Axelson H.

Clin Cancer Res. 2017 Apr 15;23(8):2105-2115. doi: 10.1158/1078-0432.CCR-16-0496. Epub 2016 Sep 23.

PMID:
27663598
10.

Co-Leadership - A Management Solution for Integrated Health and Social Care.

Klinga C, Hansson J, Hasson H, Sachs MA.

Int J Integr Care. 2016 May 23;16(2):7. doi: 10.5334/ijic.2236.

11.

Surgical outcomes in patients with cutaneous malignant melanoma in Europe - a systematic literature review.

Costa Svedman F, Spanopoulos D, Taylor A, Amelio J, Hansson J.

J Eur Acad Dermatol Venereol. 2017 Apr;31(4):603-615. doi: 10.1111/jdv.13950. Epub 2016 Oct 4. Review.

PMID:
27580240
12.

Epidemiology of cutaneous melanoma in Sweden-Stage-specific survival and rate of recurrence.

Rockberg J, Amelio JM, Taylor A, Jörgensen L, Ragnhammar P, Hansson J.

Int J Cancer. 2016 Dec 15;139(12):2722-2729. doi: 10.1002/ijc.30407. Epub 2016 Sep 22.

PMID:
27563839
13.

Multiple rare variants in high-risk pancreatic cancer-related genes may increase risk for pancreatic cancer in a subset of patients with and without germline CDKN2A mutations.

Yang XR, Rotunno M, Xiao Y, Ingvar C, Helgadottir H, Pastorino L, van Doorn R, Bennett H, Graham C, Sampson JN, Malasky M, Vogt A, Zhu B, Bianchi-Scarra G, Bruno W, Queirolo P, Fornarini G, Hansson J, Tuominen R, Burdett L, Hicks B, Hutchinson A, Jones K, Yeager M, Chanock SJ, Landi MT, Höiom V, Olsson H, Gruis N, Ghiorzo P, Tucker MA, Goldstein AM.

Hum Genet. 2016 Nov;135(11):1241-1249. Epub 2016 Jul 23.

PMID:
27449771
14.

Experiences of security and continuity of care: Patients' and families' narratives about the work of specialized palliative home care teams.

Klarare A, Rasmussen BH, Fossum B, Fürst CJ, Hansson J, Hagelin CL.

Palliat Support Care. 2017 Apr;15(2):181-189. doi: 10.1017/S1478951516000547. Epub 2016 Jul 22.

PMID:
27443410
15.

Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literature.

Svedman FC, Pillas D, Taylor A, Kaur M, Linder R, Hansson J.

Clin Epidemiol. 2016 May 26;8:109-22. doi: 10.2147/CLEP.S99021. eCollection 2016. Review.

16.

Germline CDKN2A Mutation Status and Survival in Familial Melanoma Cases.

Helgadottir H, Höiom V, Tuominen R, Nielsen K, Jönsson G, Olsson H, Hansson J.

J Natl Cancer Inst. 2016 Jun 10;108(11). pii: djw135. doi: 10.1093/jnci/djw135. Print 2016 Nov.

PMID:
27287845
17.

Prognostic and predictive value of YKL-40 in stage IIB-III melanoma.

Krogh M, Christensen I, Bouwhuis M, Johansen JS, Nørgaard P, Schmidt H, Hansson J, Suciu S, Eggermont AM, Bastholt L; Nordic Melanoma Group and EORTC Melanoma Group..

Melanoma Res. 2016 Aug;26(4):367-76. doi: 10.1097/CMR.0000000000000237.

PMID:
27076041
18.

The role of germline alterations in the DNA damage response genes BRIP1 and BRCA2 in melanoma susceptibility.

Tuominen R, Engström PG, Helgadottir H, Eriksson H, Unneberg P, Kjellqvist S, Yang M, Lindén D, Edsgärd D, Hansson J, Höiom V.

Genes Chromosomes Cancer. 2016 Jul;55(7):601-11. doi: 10.1002/gcc.22363. Epub 2016 May 2.

PMID:
27074266
19.

We Use Bioincompatible Peritoneal Dialysis Solutions.

Troidle L, Hansson J, Juergensen P, Finkelstein FO.

Semin Dial. 2016 Jul;29(4):263-4. doi: 10.1111/sdi.12490. Epub 2016 Apr 8.

PMID:
27061506
20.

Prognostic factors and disease-specific survival among immigrants diagnosed with cutaneous malignant melanoma in Sweden.

Simberg-Danell C, Lyth J, Månsson-Brahme E, Frohm-Nilsson M, Carstensen J, Hansson J, Eriksson H.

Int J Cancer. 2016 Aug 1;139(3):543-53. doi: 10.1002/ijc.30103. Epub 2016 Apr 19.

PMID:
27004457

Supplemental Content

Loading ...
Support Center